Kathleen Anne Calzone

Dr. Kathleen Anne Calzone

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 1997 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
FCFergus J. Couch
Fergus J. Couch
MDMichelle L. DeShano
Michelle L. DeShano
MBM. Anne Blackwood
M. Anne Blackwood
KCKathleen Anne Calzone
Kathleen Anne Calzone
JSJill Stopfer
Jill Stopfer
JGJudy E. Garber
Judy E. Garber
To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer, we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families.

1 December 1994 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LCLucio H. Castilla
Lucio H. Castilla
FCFergus J. Couch
Fergus J. Couch
MEMichael R. Erdos
Michael R. Erdos
KHKent F. Hoskins
Kent F. Hoskins
KCKathleen Anne Calzone
Kathleen Anne Calzone
BWBarbara L. Weber
Barbara L. Weber

1 May 1996 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FCFergus J. Couch
Fergus J. Couch
LFLinda M. Farid
Linda M. Farid
MDMichelle L. DeShano
Michelle L. DeShano
STSean V. Tavtigian
Sean V. Tavtigian
KCKathleen Anne Calzone
Kathleen Anne Calzone
BWBarbara L. Weber
Barbara L. Weber

1 May 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JLJun Li
Jun Li
SWSusan L. Woods
Susan L. Woods
SHSue Healey
Sue Healey
JBJonathan Beesley
Jonathan Beesley
XCXiaoqing Chen
Xiaoqing Chen
GCGeorgia Chenevix-Trench
Georgia Chenevix-Trench

1 June 1993 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DWD M Waterhouse
D M Waterhouse
KCKathleen Anne Calzone
Kathleen Anne Calzone
CMC Mele
C Mele
DBD E Brenner
D E Brenner
PURPOSE: Recent innovations allow the integration of microelectronics into drug packaging, providing a continuous record of the interactions of the patient with the drug package. We hypothesized that adherence to oral tamoxifen, as measured by a pressure-activated microelectronic monitoring device, would be significantly discrepant from traditional measures of patient adherence, ie, patient self-report (SR) and pill counts (PCs). PATIENTS AND METHODS: Twenty-six patients receiving oral tamoxifen therapy were assessed by patient SR, PCs, and Medication Event Monitoring System (MEMS; Aprex Corp, Fremont, CA) microelectronic monitoring. A microprocessor in the MEMS cap recorded each opening as a presumptive dose, listing the date, time, and duration of opening for later retrieval on a microcomputer. Patients were not informed that their adherence was to be monitored electronically or that PCs would be performed. RESULTS: A total of 2,102 days (70.1 months) of tamoxifen therapy were monitored; patients were monitored for a mean of 2.92 months of tamoxifen therapy. SR adherence to oral tamoxifen was significantly higher than that suggested by either PCs (SR missed doses only v PC, P = .008) or MEMS adherence monitoring (SR missed doses only v MEMS missed doses only, P = .005; SR dosing-interval errors only v MEMS dosing-interval errors only, P < .0001; SR all dosing errors v MEMS all dosing errors, P < .0005). PC data also suggested significantly higher adherence rates than MEMS monitoring. CONCLUSION: Microelectronic adherence monitoring provides both confirmatory and complimentary data regarding adherence behavior, while also allowing for the evaluation of patterns of nonadherence. Patient SRs and PCs likely overestimate the degree to which patients adhere to their tamoxifen regimen.

15 February 1995 in JAMA
Verified
Journal Article
Closed access
PDF file
KHKent F. Hoskins
Kent F. Hoskins
JSJill E. Stopfer
Jill E. Stopfer
KCKathleen Anne Calzone
Kathleen Anne Calzone
SMSofia D. Merajver
Sofia D. Merajver
TRTimothy R. Rebbeck
Timothy R. Rebbeck
BWBarbara L. Weber
Barbara L. Weber
More women in all risk categories are seeking information regarding their individual breast cancer risk, and there is a need for their primary care clinicians to be able to assess familial risk factors for breast cancer, provide individualized risk information, and offer surveillance recommendations. Estimates of the number of women with a family history of breast cancer range from approximately 5% to 20%, depending on the population surveyed. Many of these women will not have a family history that suggests the presence of a highly penetrant breast cancer susceptibility gene. However, a small subset of such women will come from families with a striking incidence of breast and other cancers often associated with inherited mutations. The development and refinement of risk prediction models provide an epidemiologic basis for counseling women with a family history that does not appear related to a dominant susceptibility gene. In contrast, the recent isolation ofBRCA1, the localization ofBRCA2, and the acknowledgment that additional breast cancer susceptibility genes must exist provide a molecular basis for counseling some high-risk women. We present a guide for primary care clinicians that may be helpful in defining families as moderate or high risk, in determining individual risk in women with a family history of breast cancer based on this distinction, and for counseling women in a setting where the data necessary to design surveillance and prevention strategies are lacking. We include criteria for selecting women who may be candidates for detection of inherited mutations in breast cancer susceptibility genes. (JAMA. 1995;273:577-585)